J9207 Ixabepilone injection
Also known as: ixabepilone, Ixempra
Intravenous injection of ixabepilone, a semisynthetic microtubule-stabilizing agent.
In Plain Language
microtubule-stabilizing cancer drug; breast cancer chemotherapy
Clinical Context
Used for metastatic breast cancer as monotherapy or with other agents.
RVU Information
CPT J9207 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9207?
CPT J9207 (Ixabepilone injection) is a J Codes (Drugs) code. Intravenous injection of ixabepilone, a semisynthetic microtubule-stabilizing agent.
How is J9207 administered?
CPT J9207 is administered by a healthcare provider, typically via injection or infusion. Used for metastatic breast cancer as monotherapy or with other agents. It is used by Oncology, Medical Oncology.
When is CPT J9207 used?
Used for metastatic breast cancer as monotherapy or with other agents.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.